CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
108.24
+0.11 (+0.10%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close108.13
Open108.01
Bid0.00 x 800
Ask0.00 x 1300
Day's Range107.27 - 108.59
52 Week Range82.26 - 110.70
Volume191,230,586
Avg. Volume13,366,023
Market Cap77.036B
Beta (5Y Monthly)N/A
PE Ratio (TTM)13.31
EPS (TTM)N/A
Earnings DateJan 28, 2020 - Feb 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est103.40
  • Moody's

    Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • ACCESSWIRE

    NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / January 7, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Celgene Corporation (CELG) shares. Investors, who purchased shares of Celgene Corporation (CELG) in 2016 or earlier and continue to hold any of your NASDAQ: CELG shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On March 29, 2018, a lawsuit was filed against Celgene Corporation over alleged securities laws violations.

  • Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
    Investor's Business Daily

    Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

    Pharmaceutical company Bristol-Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

  • An Unusual Investment With 125% Upside
    GuruFocus.com

    An Unusual Investment With 125% Upside

    Discussion of the Bristol-Myers contingent value right Continue reading...

  • GlobeNewswire

    NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.

  • Reuters

    Bristol-Myers business development head Biondi departs

    Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015. Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28.

  • Biotech ETFs Hit New Highs on Deal Activities
    Zacks

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

  • TheStreet.com

    Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise

    Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year.

  • Reuters

    Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

    Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year. The treatment, liso-cel, is a newer type of immunotherapy known as CAR-T cell therapy, that takes immune cells from a patient, engineers them to better recognize and attack cancer and infuses them back into the patient.

  • Moody's

    Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3

    Moody's Investors Service ("Moody's") upgraded the senior unsecured ratings of Celgene Corporation to A3 from Baa2. Moody's anticipates that the ratings of Celgene will eventually be withdrawn. The upgrade of the ratings follows the recent acquisition of Celgene by Bristol-Myers Squibb Company ("Bristol") in which Celgene became a subsidiary of Bristol.

  • $50M deal could expand NanoString Technologies diagnostic test into more markets
    American City Business Journals

    $50M deal could expand NanoString Technologies diagnostic test into more markets

    NanoString, which creates devices for molecular diagnostics and research tools to understand diseases and develop drugs, will record more than $100 million in revenue this year.

  • Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
    TheStreet.com

    Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

    There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.

  • Here is the 17th Most Popular Stock Among 752 Hedge Funds
    Insider Monkey

    Here is the 17th Most Popular Stock Among 752 Hedge Funds

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

  • Benzinga

    The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

    Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a  positive ...

  • Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
    Zacks

    Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

    Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.

  • Barrons.com

    Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut

    The contingent value rights debuted with a bang on the New York Stock Exchange Thursday, with heavy trading volume of 101 million amid selling by index funds.

  • Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy
    Investor's Business Daily

    Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy

    Amgen raised its full-year outlook Thursday after the biotech company wrapped its acquisition of psoriasis treatment Otezla in the wake of Bristol-Myers Squibb's takeover of Celgene.

  • Biotech ETF (BBH) Hits New 52-Week High
    Zacks

    Biotech ETF (BBH) Hits New 52-Week High

    This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

  • Reuters

    Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

    Amgen Inc on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla. Bristol-Myers Squibb Co, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through. Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its prior range of $14.20 to $14.45.

  • PR Newswire

    Amgen Completes Acquisition Of Otezla® (apremilast)

    THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY), which was completed on Nov. 20. Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.

  • TheStreet.com

    Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain

    Bristol-Myers Squibb shares edged higher Thursday after the pharmaceutical group said it has completed its $74 billion acquisition of cancer drug specialist Celgene Corp.

  • Barrons.com

    An All-or-Nothing Bet on 3 Drugs in Celgene’s Pipeline

    A new security issued as part of the deal with Bristol-Myers Squibb amounts to potentially lucrative lottery ticket.

  • MarketWatch

    Bristol-Myers Squibb completes $74 billion acquisition of Celgene

    Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp. , nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission cleared the merger in a statement on Friday. The FTC required Bristol-Myers and Celgene sell the rights to Otezla, Celgene's psoriasis drug. Amgen Inc. agreed to buy the rights to the drug for $13.4 billion in August. Shares of Bristol-Myers and Celgene are up slight in after-hours trading on Wednesday.